跳转至内容
Merck

SML0042

Sigma-Aldrich

Lazabemide hydrate

≥97% (HPLC)

别名:

N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide hydrate, Ro 19-6327 hydrate

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C8H10ClN3O · xH2O
分子量:
199.64 (anhydrous basis)
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
价格与库存信息目前不能提供

方案

≥97% (HPLC)

表单

powder

储存条件

desiccated

颜色

white to tan

溶解性

DMSO: ≥22 mg/mL

创始人

Roche

储存温度

room temp

SMILES字符串

O.NCCNC(=O)c1ccc(Cl)cn1

InChI

1S/C8H10ClN3O.H2O/c9-6-1-2-7(12-5-6)8(13)11-4-3-10;/h1-2,5H,3-4,10H2,(H,11,13);1H2

InChI key

JYWYNPKXSLPWGV-UHFFFAOYSA-N

应用

Lazabemide hydrate may be used in cell signaling studies.

生化/生理作用

Lazabemide is a selective and reversible monoamine oxidase B (MAO-B) inhibitor and Anti-Parkinson. Also it inhibits monoamine uptake at high concentrations (IC50 values are 86, 123 and > 500 μM for noradrenalin, serotonin and dopamine uptake respectively).
Lazabemide is effective in treatment of Alzheimer′s disease[1] and in combination with nicotine replacement therapy aids in smoking cessation.[2]
Selective MAO-B inhibitor; Antiparkinson

特点和优势

This compound is featured on the Dopamine and Norepinephrine Metabolism and Histamine Synthesis and Metabolism pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

象形图

Exclamation mark

警示用语:

Warning

危险声明

危险分类

Acute Tox. 4 Oral - Eye Irrit. 2

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

N Andrés et al.
Neuroscience, 101(4), 807-810 (2000-12-13)
Aged rats may be behaviorally classified as either cognitively impaired or unimpaired based upon their performance in the Morris water maze task. In aged Long-Evans rats, emergence of functional deficits has been related to the increase in the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic
D H Fitzgerald et al.
Journal of neural transmission (Vienna, Austria : 1996), 109(3), 251-265 (2002-04-17)
The specific activity and kinetic behaviour of semicarbazide-sensitive amine oxidase (EC 1.4.3.6; SSAO) towards benzylamine, in the rat heart, is affected by in vivo treatment with the non-selective monoamine oxidase (MAO) inhibitor tranylcypromine, but not by the selective MAO-A and
Ivan Berlin et al.
Addiction (Abingdon, England), 97(10), 1347-1354 (2002-10-03)
Previous research has shown that smokers have reduced brain and platelet monoamine oxidase B (MAOB) activity. This is probably due to some components of tobacco smoke. When smokers quit, MAOB activity returns to normal. Reduced MAO activity may increase nicotine's
R P Mason et al.
Biochemical pharmacology, 60(5), 709-716 (2000-08-06)
Free radical-induced damage to lipid and protein constituents of neuronal membranes contributes to the pathophysiology of neurodegenerative diseases, including Alzheimer's disease (AD). The development of an effective inhibitor of oxidative stress represents an important goal for the treatment of AD.
Yuji Kitaichi et al.
European journal of pharmacology, 532(3), 236-245 (2006-02-21)
We investigated the effects of clorgyline [a selective MAO (monoamine oxidase inhibitor)-A inhibitor] and lazabemide (a selective MAO-B inhibitor) on extracellular serotonin, dopamine and noradrenaline concentrations in the medial prefrontal cortex after 1-week treatment with subchronic 0.2% or 0.05% Li2CO3

Questions

Reviews

No rating value

Active Filters

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持